Caplacizumab Is Effective in Treating Immune-Mediated Thrombotic Thrombocytopenic Purpura in Real-World Scenarios and May Lower Mortality: An Aggregative Analysis von Völker, Linus A., Balduin, Gesa, Kühne, Lucas, Kaufeld, Jessica, Schönermarck, Ulf, Menne, Jan, Knöbl, Paul, Brinkkoetter, Paul

Volltext

Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura von Völker, Linus A., Kaufeld, Jessica, Balduin, Gesa, Merkel, Lena, Kühne, Lucas, Eichenauer, Dennis A., Osterholt, Thomas, Hägele, Holger, Kann, Martin, Grundmann, Franziska, Kolbrink, Benedikt, Schulte, Kevin, Gäckler, Anja, Kribben, Andreas, Boss, Kristina, Potthoff, Sebastian A., Rump, Lars C., Schmidt, Tilman, Mühlfeld, Anja S., Schulmann, Karsten, Hermann, Matthias, Gaedeke, Jens, Sauerland, Kristin, Bramstedt, Jörn, Hinkel, Ulrich P., Miesbach, Wolfgang, Bauer, Frederic, Westhoff, Timm H., Bruck, Heike, Buxhofer-Ausch, Veronika, Müller, Tobias J., Wendt, Ralph, Harth, Ana, Schreiber, Adrian, Seelow, Evelyn, Tölle, Markus, Gohlisch, Christopher, Bieringer, Markus, Geuther, Gesa, Jabs, Wolfram J., Fischereder, Michael, von Bergwelt-Baildon, Anke, Schönermarck, Ulf, Knoebl, Paul, Menne, Jan, Brinkkoetter, Paul T., Özcan, Fedai, Markau, Silke, Girndt, Matthias, Felten, Helmut, Hausberg, Martin, Brand, Marcus, Gerth, Jens, Bommer, Martin, Zschiedrich, Stefan, Schneider, Johanna, Elitok, Saban, Gawlik, Alexander, Schwenger, Vedat, Roeder, Maximilian, Radermacher, Jörg, Morgner, Anke, Herbst, Regina, von Auer, Charis

Volltext